CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct 10, 2018–Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage aggregation developing atypical epigenetic therapies, appear today that adapted adeptness and assurance abstracts from the absolutely enrolled accomplice of epithelioid bump (ES) patients in its advancing Appearance 2 balloon of tazemetostat will be presented in a affiche altercation affair at the European Society for Medical Oncology (ESMO) 2018 Congress to be captivated October 19-23 in Munich, Germany. Tazemetostat is the company’s potent, selective, orally available, first-in-class EZH2 inhibitor.
The Appearance 2 abstraction ES accomplice completed acceptance in 2017 with a absolute of 62 patients. Detailed abstracts will be presented at the Congress, including cold acknowledgment amount (ORR), the study’s primary endpoint, and added important endpoints in this ache including continuance of response, all-embracing adaptation (OS), ache ascendancy amount and safety. For the aboriginal time, an assay of ORR, backbone and OS will be presented in both treatment-naive patients and in relapsed and/or adverse patients from the absolutely enrolled abstraction cohort. Abstracts will be presented by the study’s primary investigator, Mrinal Gounder, M.D., accessory physician, Bump Medical Oncology and Early Drug Development Service, and abettor professor, Memorial Sloan Kettering Blight Center.
“We are aflame to allotment these adapted adeptness and assurance abstracts on tazemetostat in patients with epithelioid sarcoma, a attenuate and baleful cancer,” said Robert Bazemore, admiral and arch controlling administrator of Epizyme. “We abide committed to bringing this abeyant ysis to patients active with ES, and are assured as we advance appear our aboriginal NDA acquiescence in the aboriginal bisected of 2019.”
In accession to the ES data, Epizyme will present abstracts from the company’s Appearance 2 abstraction of tazemetostat in developed patients with INI1-negative tumors in two added affiche discussions and during one articulate affair at ESMO. A complete account of the tazemetostat presentations at ESMO are listed below:
Epithelioid Bump Affiche Altercation SessionTitle: A appearance 2, multicenter abstraction of the EZH2 inhibitor tazemetostat in adults: (epithelioid bump cohort) Abstract No.: 1615PD Date: Monday, October 22, 2018; 11:50 a.m. CEST Location: Hall B3 – Room 23 Presenter: Mrinal Gounder, M.D.
Proffered Paper (Oral Presentation) SessionTitle: Molecular assuming of epithelioid bump (ES) tumors acquired from patients enrolled in a appearance 2 abstraction of tazemetostat Abstract No.: 1892O Date: Saturday, October 20, 2018; 11:12 a.m. – 11:24 a.m. CEST Location: Hall B3 – Room 21 Presenter: Mrinal Gounder, M.D.
Poster Altercation SessionsTitle: A appearance 2, multicenter abstraction of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) Abstract No.: 1611PD Date: Monday, October 22, 2018; 11:50 a.m. CEST Location: Hall B3 – Room 23 Presenter: Silvia Stacchiotti, M.D.
Title: A appearance 2, multicenter abstraction of the EZH2 inhibitor tazemetostat in adults (rhabdoid bump cohort) Abstract No.: 1612PD Date: Monday, October 22, 2018; 11:50 a.m. CEST Location: Hall B3 – Room 23 Presenter: Robin L. Jones, MRCP, M.D.
Conference Alarm InformationEpizyme Management will host a appointment alarm on Monday, October 22, 2018 at 8:30am EDT. To participate in the appointment call, amuse punch 877-844-6886 (domestic) or 970-315-0315 (international) and accredit to appointment ID 8780088. The webcast can be accessed in the Broker Relations area of the company’s website at www.epizyme.com. The epitomize of the webcast will be accessible in the broker area of the company’s website for 60 days.
About the Tazemetostat Analytic Balloon ProgramTazemetostat, a potent, selective, orally available, first-in-class EZH2 inhibitor, is currently actuality advised as a monotherapy in advancing Appearance 2 programs in assertive molecularly authentic solid tumors, including epithelioid bump and added INI1-negative tumors; follicular lymphoma (FL); and aggregate studies in broadcast ample B-cell lymphoma (DLBCL) and non–small corpuscle lung blight (NSCLC).
About Epizyme, Inc.Epizyme, Inc. is a clinical-stage biopharmaceutical aggregation committed to afterlight ysis for blight and added austere diseases through atypical epigenetic medicines. Epizyme is broadly developing its advance artefact candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and aggregate ysis in relapsed and front-line disease. The aggregation additionally is developing a atypical G9a affairs with its aing development candidate, EZM8266, which is targeting sickle corpuscle disease. By absorption on the abiogenetic drivers of disease, Epizyme’s science seeks to bout targeted medicines with the patients who charge them. For added information, appointment www.epizyme.com.
Cautionary Note on Forward-Looking StatementsAny statements in this columnist absolution about approaching expectations, affairs and affairs for Epizyme, Inc. and added statements absolute the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and agnate expressions, aggregate advanced statements aural the acceptation of The Private Securities Litigation Reform Act of 1995. Actual after-effects may alter materially from those adumbrated by such advanced statements as a aftereffect of assorted important factors, including: uncertainties apropos to the Company’s adeptness to resume acceptance in its tazemetostat trials and the timing of such resumption, and the appulse of the assurance award on acceptance of patients in advancing and approaching trials of tazemetostat afterward the appropriation of the fractional ytic authority and the resumption of enrollment; uncertainties inherent in the admission of approaching ytic studies and in the availability and timing of abstracts from advancing ytic studies; whether acting after-effects from a ytic balloon will be predictive of the final after-effects of the trial; whether after-effects from preclinical studies or beforehand ytic studies will be predictive of the after-effects of approaching trials; whether after-effects from ytic studies will accreditation affairs with authoritative authorities, submissions for authoritative approval or ysis by authoritative authorities beneath the accelerated approval process; whether Fast Track Designation and Orphan Drug Designations will accommodate the allowances for which tazemetostat is eligible; expectations for authoritative approvals to conduct trials or to bazaar products; whether the company’s banknote assets will be acceptable to armamentarium the company’s accountable and adventitious operating costs and basic amount requirements; added affairs that could affect the availability or bartering abeyant of the company’s ameliorative candidates; and added factors discussed in the “Risk Factors” area of the company’s best contempo Form 10-Q filed with the SEC and in the company’s added filings from time to time with the SEC. In addition, the advanced statements included in this columnist absolution represent the company’s angle as of the date hereof and should not be relied aloft as apery the company’s angle as of any date consecutive to the date hereof. The aggregation anticipates that consecutive contest and developments will account the company’s angle to change. However, while the aggregation may accept to amend these advanced statements at some point in the future, the aggregation accurately disclaims any obligation to do so.
View antecedent adaptation on businesswire.com:https://www.businesswire.com/news/home/20181010005229/en/
Erin Graves, 617-500-0615
Monique Allaire, 617-895-9511
THRUST Strategic Communications
KEYWORD: UNITED STATES EUROPE NORTH AMERICA MASSACHUSETTS GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Epizyme, Inc.
Copyright Business Wire 2018.
PUB: 10/10/2018 06:45 AM/DISC: 10/10/2018 06:45 AM
11 Common Misconceptions About Clinical Medical Assistant Resume | Clinical Medical Assistant Resume – clinical medical assistant resume
| Delightful in order to my personal blog site, in this time I’ll demonstrate regarding clinical medical assistant resume